Endothelial dysfunction indicators and hemorheological properties in acute ischemic stroke

Cover Page

Abstract

We evaluated endothelial dysfunction and hemorheological indicators in acute ischemic stroke. The hemorheological indicators (blood viscosity, plasma viscosity, hematocrit, erythrocyte aggregation and deformability, fibrinogen concentration) were assessed three times: within the first 12 hours of the onset of symptoms and on day 3–5 and day 18–20 after hospitalization; the endothelial dysfunction indicators were examined on day 15–17 using a cuff test. Patients in the acute phase of ischemic stroke had pronounced changes in the hemorheological indicators that could be characterized as high blood viscosity syndrome. For example, we observed increased platelet aggregation that plays a key role in the blood viscosity value in blood vessels with low shear rates. We also observed reduced erythrocyte deformability at high shear rates. After treatment, patients had positive clinical dynamics according to neurological scales. Dynamics of the hemorheological indicators was as follows: erythrocyte aggregation decreased; blood viscosity tended to reduce; however, erythrocyte deformability tended to worsen. Therefore, the pathological changes in elastic properties of the erythrocyte membranes in stroke are not corrected by ongoing standard therapy. Assessment of the endothelial functional activity revealed that stroke patients had a decreased brachial artery response associated with reactive hyperemia and an increased response to the nitroglycerin test. The study demonstrated that treated patients with ischemic stroke had endothelial functional activity changes that manifested as a statistically significant increase in the endothelial dysfunction index. We concluded that the approach to stroke treatment requires complex pharmacological correction, in particular by means with the proven hemorheological activity.

About the authors

M. N. Azhermacheva

Chair of Neurology and Neurosurgery, Siberian State Medical University, Tomsk

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

V. M. Alifirova

Chair of Neurology and Neurosurgery, Siberian State Medical University, Tomsk

Email: platonova@neurology.ru
Russian Federation

D. M. Plotnikov

Chair of Neurology and Neurosurgery, Siberian State Medical University, Tomsk

Email: platonova@neurology.ru
Russian Federation

O. I. Aliev

Laboratory of Circulation Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk

Email: platonova@neurology.ru
Russian Federation

M. A. Solovtsov

Regional Vascular Center for Treatment of Acute Cerebrovascular Diseases, Tomsk

Email: platonova@neurology.ru
Russian Federation

K. I. Burkova

Regional Vascular Center for Treatment of Acute Cerebrovascular Diseases, Tomsk

Email: platonova@neurology.ru
Russian Federation

M. B. Plotnikov

Laboratory of Circulation Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk

Email: platonova@neurology.ru
Russian Federation

References

  1. Головченко Ю.И., Трещинская М.А. Обзор современных представлений об эндотелиальной дисфункции. Consilium medicum Ukraina 2008; 2 (11): 38–40.
  2. Добровольский Н.А., Лопухин Ю.М., Парфенов А.С., Пешков А.В.Анализатор вязкости крови. Реологические исследования в медицине. М., 1997: 45–51.
  3. Домашенко М.А. Состояние функции эндотелия при ишемических нарушениях мозгового кровообращения. Неврологич. журн.2007; 12 (6): 10–14.
  4. Ионова В.Г., Суслина 3.А. Реологические свойства крови при ишемических нарушениях мозгового кровообращения. Неврологич. журн. 2002, 3: 4–10.
  5. Коноплева Л.Ф. Эндотелиальная дисфункция в патогенезе сердечно-сосудистых заболеваний и методы ее коррекции. Therapia 2011; 3 (56): 26–30.
  6. Мельников А.А. Реологические свойства крови у спортсменов. Ярославль: Изд. ЯГПУ, 2008: 210–223.
  7. Муравьев А.В., Чепоров С.В. Гемореология (экспериментальные и клинические аспекты реологии крови). Ярославль: Изд. ЯГПУ, 2009.
  8. Плотников М.Б., Алиев О.И., Попель Ф.В. Модификация микроколориметра МКМФ-1 для регистрации агрегации эритроцитов. Клинич. лабор. диагностика 1995; 3: 57–58.
  9. Покровский М.В. Пат. 2301015 Российская Федерация, МПК A61B5/02. Способ оценки эндотелиальной дисфункции. Покровский М.В. и др.: заявитель и патентообладатель КГМУ (RU). № 2005113243/14; заявл. 04.05.2005 опубл. 20.06.2006.
  10. Поливода С.Н. Ремоделирование артериальных сосудов у больных гипертонической болезнью – взгляд сквозь призму молекулярных механизмов. Артериальная гипертензия 2009; 4 (6).
  11. Суслина З.А, Ерофеева А.В., Танашян М.М., Ионова В.Г. Гемореология и гемостаз при ишемических инсультах. Неврологич. вестник им. В.М. Бехтерева 2005; 37(3/4): 5–10.
  12. Суслина З.А., Максимова М.Ю., Ионова В.Г., Танашян М.М. и др. Дисрегуляция гемореологии и гемостаза при артериальной гипертонии. Кардиоваскулярная терапия и профилактика 2003; 2 (4): 54–57.
  13. Суслина З.А., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. М.:Медицинская книга, 2005.
  14. Танашян М.М., Суслина З.А., Ионова В.Г. и др. Состояние функции эндотелия у больных ишемическим инсультом при различной степени атеросклеротического поражения сонных артерий. Неврологический вестник. Журнал им. В.М. Бехтерева 2007; 1 (39):12–16.
  15. Танашян М.М. Гемостаз, гемореология и атромбогенная активность сосудистой стенки в ангионеврологии. Анн. клинич. и эксперим. неврол. 2007; 1 (2): 29–33.
  16. Шляхто Е.В., Конради А.О., Моисеева О.М. Молекулярно-генетические и клеточные аспекты ремоделирования сердца и сосудов при гипертонической болезни (обзор). Терапевтич. архив 2004; 76 (6): 51–58.
  17. Adams H.P., Bendixen B.H., Kappelle L.J. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41.
  18. Baskurt O.K. Handbook of hemorheology and hemodynamics. Niderland:IOS Press, 2007: 21–114.
  19. Bessis M., Mohandas N. A diffractometric method for the measurement of cellular deformability. Blood Cells 1975; 1: 307–313.
  20. Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–1115.
  21. Cherian P., Hankey G., Eikelboom J. et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003; 34: 2132–2137.
  22. Coull B.M., Beamer N., P. de Garmo et al. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 1991; 22: 162–168.
  23. Dashe J.F. Hyperviscosity and stroke. In: Bogousslavsky J., Caplan L. (eds.) Uncommon causes of stroke, 3’’ed. New York: Cambridge University Press, 2008: 347–357.
  24. Dintenfass L. Rheology of blood in diagnostic and preventative medicine. London, 1976.
  25. Fisher M., Meiselman H.J. Hemorheological factors in cerebral ischemia. Stroke 1991; 22: 1164–1169.
  26. Global atlas on cardiovascular disease prevention and control. Geneva:World Health Organization; 2011.
  27. Kwaan H.C., Bongu A. The hyperviscosity syndromes. Semin. Thromb. Hemost. 1999; 25, Suppl. 2: 199–208.
  28. Lenz C. Blood viscosity modulates tissue perfusion: sometimes and somewhere. Transfus. Altern. Transfus. Med. 2008; 9 (4): 265–272.
  29. Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2013; 380, I. 9859: 2095–2128.
  30. Mark A., Sader, David S., Celermajer D. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovascular Research 2002; 53: 597–660.
  31. Plasenzotti R., Stoiber B., Posch M. et al. Red blood cell deformability and aggregation behavior in different animal species. Clin. Hemorheol. Microcirc 2004; 31 (2): 105–111.
  32. Popel A.S. Johnson P.C. Microcirculation and Hemorheology. Annu. Rev. Fluid Mech 2005; 37: 43–69.
  33. Raitakari O.T., Celermajer D. S. Flow-mediated dilatation. Br J Clin Pharmacol 2000; 50 (5): 397–404.
  34. Sigle J.P., Buser А. Hyperviscosity syndrome. Blood 2011; 117 (5):1446–1448.
  35. Stoltz J.F., Donner M. New trends in clinical hemorheology: an introduction to the concept of the hemorheological profile. Schweiz. Med. Wochenschr.1991; 43, Suppl. 1: 41–49.
  36. Tikhomirova I.A., Oslyakova A.O., Mikhailova S.G. Microcirculation and blood rheology in patients with cerebrovascular disorders. Clin. Hemorheol. Microcirc. 2011; 49 (1–4): 295–305.
  37. Tsuda Y., Satoh K., Kitadai M., Takahashi T. Hemorheologic profiles of plasma fibrinogen and blood viscosity from silent to acute and chronic cerebral infarctions. J. Neurol. Sci. 1997; 147: 49–54.

Statistics

Views

Abstract: 817

PDF (Russian): 591

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2017 Azhermacheva M.N., Alifirova V.M., Plotnikov D.M., Aliev O.I., Solovtsov M.A., Burkova K.I., Plotnikov M.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies